In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cyberonics' Two-Front War

Executive Summary

Most medical device executives are reluctant to say anything that could in any way be construed as critical of the FDA or the agencies that determine reimbursement coverage decision. But not Robert "Skip" Cummins, president and CEO of neurostimulation pioneer Cyberonics. For the past two years, Cummins has been waging what has been a virtual one-man war with the FDA and major payers to make sure that psychiatrists and their patients have access to the only FDA-approved treatment for severe treatment resistant depression.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts